Logo image of ODT

Odonate Therapeutics Inc (ODT) Stock Fundamental Analysis

NASDAQ:ODT - Nasdaq - Common Stock

1.12  -0.05 (-4.27%)

After market: 1.11 -0.01 (-0.89%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ODT. ODT was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of ODT is average, but there are quite some concerns on its profitability. ODT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ODT has reported negative net income.
ODT Yearly Net Income VS EBIT VS OCF VS FCFODT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -96.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ODT Yearly ROA, ROE, ROICODT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ODT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ODT Yearly Profit, Operating, Gross MarginsODT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020

More info and screens

5

2. Health

2.1 Basic Checks

ODT has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ODT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ODT Yearly Shares OutstandingODT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M
ODT Yearly Total Debt VS Total AssetsODT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

ODT has an Altman-Z score of -7.42. This is a bad value and indicates that ODT is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for ODT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.42
ROIC/WACCN/A
WACCN/A
ODT Yearly LT Debt VS Equity VS FCFODT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M

2.3 Liquidity

A Current Ratio of 3.29 indicates that ODT has no problem at all paying its short term obligations.
ODT has a Quick Ratio of 3.29. This indicates that ODT is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
ODT Yearly Current Assets VS Current LiabilitesODT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

ODT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.46%, which is quite impressive.
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ODT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.53%
EPS Next 2Y40.68%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ODT Yearly Revenue VS EstimatesODT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
ODT Yearly EPS VS EstimatesODT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ODT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ODT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ODT Price Earnings VS Forward Price EarningsODT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.58
ODT Per share dataODT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ODT's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.68%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ODT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Odonate Therapeutics Inc

NASDAQ:ODT (1/14/2022, 8:44:12 PM)

After market: 1.11 -0.01 (-0.89%)

1.12

-0.05 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/bmo
Inst Owners0.06%
Inst Owner Change0%
Ins Owners20.59%
Ins Owner Change0%
Market Cap43.11M
Analysts46.67
Price Target4.08 (264.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB N/A
EV/EBITDA 0.58
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.85
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -7.42
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.22%
EPS Next Y54.53%
EPS Next 2Y40.68%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A